Sign in
ONCY Stock Price, Chart, Stats & News
Oncolytics Biotech Inc.
Save
Oncolytics Biotech Inc. (ONCY) does not currently pay a dividend.
83.06M
Market cap
–
Current P/E
45.45x
Forward P/E
ONCY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.41% |
ROA | -234.24% |
ROE | -755.18% |
D/E | 7.26x |
Interest coverage ratio | – |
ONCY valuation
P/E | – |
P/S | – |
P/B | 1027.58x |
P/CF | -4.47x |
P/FCF | -4.42x |
P/OCF | -4.47x |
PEG | 0.45x |
EV multiple | -3.63x |
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Similar securities
Based on sector and market capitalization
Report issue